## Sun Pharmaceutical Industries Limited (SUNPHARMA) Stock Analysis Report - December 20, 2024

**1. Company Overview:**

Sun Pharmaceutical Industries Limited (SUNPHARMA) is a leading pharmaceutical company operating in the Pharmaceuticals industry.  Listed on the NSE since February 8, 1995, it holds a significant position within the Indian pharmaceutical sector, known for its diverse product portfolio and global presence.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,810.00       |                                                                      |
| Percentage Change (PChange) | -0.73%          | Negative change indicating a slight downward trend in the day's trading. |
| Pre-Open Activity          | ₹1,823.30       |  Pre-open price higher than the closing price, suggesting potential buying interest.  |
| Week High                    | ₹1,960.35       | High reached on September 30, 2024.                               |
| Week Low                     | ₹1,208.55       | Low reached on December 21, 2023.  Significant volatility observed. |
| VWAP                        | ₹1,808.38       | Volume Weighted Average Price for the day.                           |
| Sector PE                   | 38.74           | Price-to-Earnings ratio for the sector.                             |
| Symbol PE                   | 39.28           | Price-to-Earnings ratio for SUNPHARMA.                             |
| Delivery Percentage         | 62.79%          |  High delivery percentage suggests a significant portion of trades were genuine investments. |
| Market Depth                | Low              |  The provided data shows minimal buy/sell orders in the market depth order book, indicating low liquidity. |


**3. Financial Performance:**

The following table summarizes the financial performance of SUNPHARMA over the past five quarters.  Note that the data shows profit after tax and EPS are positive, but the provided data does not allow for a detailed analysis of key financial ratios (e.g., ROE, ROA, Debt-to-Equity).  Further investigation is needed to fully assess financial health.

| Quarter      | From Date     | To Date       | Income (₹)    | Expenditure (₹) | Profit After Tax (₹) | Diluted EPS |
|--------------|---------------|---------------|---------------|-----------------|-----------------------|-------------|
| Q1 FY25      | 01-Jul-2024   | 30-Sep-2024   | 521,401        | 431,837          | 86,329                 | 3.6         |
| Q4 FY24      | 01-Apr-2024   | 30-Jun-2024   | 458,081        | 432,289          | 23,782                 | 1           |
| Q3 FY24      | 01-Jan-2024   | 31-Mar-2024   | 575,802        | 435,624          | 86,760                 | 3.6         |
| Q2 FY24      | 01-Oct-2023   | 31-Dec-2023   | 515,055        | 432,927          | 72,131                 | 3           |
| Q1 FY24      | 01-Jul-2023   | 30-Sep-2023   | 520,275        | 429,623          | 88,863                 | 3.7         |


**4. Corporate Actions and Announcements:**

SUNPHARMA has consistently declared dividends over the past few years.  Recent announcements include shareholder meetings and general updates, but no significant announcements impacting stock performance are immediately apparent from the provided data.  The most recent dividend ex-date was July 12, 2024 (₹5 per share).

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|--------------|--------------------------|--------|-------------------------------|-------|
| 30-Sep-2023  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|
| 31-Dec-2023  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|
| 31-Mar-2024  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|
| 30-Jun-2024  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|
| 30-Sep-2024  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|

Promoter holding remains stable over the observed period.

**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the week's high and low prices. The CM Annual Volatility of 22.35% further confirms this.  The risk-reward profile is currently skewed towards higher risk due to this volatility and the limited market depth.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Strong promoter holding.
* Established player in the pharmaceutical sector.

**8. Disadvantages and Risks:**

* High volatility.
* Limited market depth, implying lower liquidity.
* Inconsistent quarterly financial performance (requires further investigation beyond the provided data).


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price decline and low market depth suggest caution.  Waiting for clearer price momentum is advisable.

* **Medium-term (3 to 12 months): Hold.**  Further analysis of financial ratios and industry trends is needed to justify a buy recommendation.  The consistent dividend payouts offer some support.

* **Long-term (1 year and beyond): Hold.**  SUNPHARMA's position in the pharmaceutical sector offers long-term potential, but a thorough fundamental analysis is crucial before a buy recommendation can be made.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 6/10 (Positive profit after tax and EPS, but requires deeper ratio analysis)
* Market Performance: 7/10 (Consistent dividend payouts, but recent price volatility is a concern)
* Volatility and Risk: 4/10 (High volatility and low market depth present significant risk)
* Corporate Actions and Governance: 8/10 (Consistent dividend history, regular announcements)
* Shareholding Patterns: 9/10 (Stable promoter holding)

**Analysis Score (out of 10): 8**

* Completeness and utilization of data: 9/10 (Most data points were used effectively)
* Accuracy and clarity of analysis: 8/10 (Analysis is clear, but some limitations due to incomplete financial data)
* Professional formatting: 9/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the available data, SUNPHARMA is currently a **Hold** for all investment horizons.  While the company shows some strengths (consistent dividends, strong promoter holding), the high volatility, low market depth, and the need for further financial analysis outweigh the positives in the short to medium term.  A more comprehensive financial analysis, including key ratios and industry benchmarks, is recommended before considering a buy recommendation for any investment horizon.
